Agomelatine, a melatonin receptor agonist with 5-HT2C receptor antagonist properties, protects the developing murine white matter against excitotoxicity

European Journal of Pharmacology

Volumn 588, Issue 1, 2008, Pages 58-63

  Gressens, Pierre ^a,b,c,d   Schwendimann, Leslie ^a,b,d   Husson, Isabelle ^a,b,c,d   Sarkozy, Gergely ^e   Mocaer, Elizabeth ^f   Vamecq, Joseph ^a   Spedding, Michael ^f  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d PremUP   (France)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

Agomelatine; Cerebral palsy; Ibotenate; N methyl d aspartate; Periventricular leukomalacia

Indexed keywords

AGOMELATINE; IBOTENIC ACID; LUZINDOLE; MELATONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CYST; BRAIN DAMAGE; BRAIN DEVELOPMENT; CONTROLLED STUDY; DRUG EFFECT; EXCITOTOXICITY; MOUSE; NEUROPROTECTION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; WHITE MATTER;

ACETAMIDES; ANIMALS; BRAIN; BRAIN DISEASES; EXCITATORY AMINO ACID AGONISTS; IBOTENIC ACID; MELATONIN; MICE; NEUROPROTECTIVE AGENTS; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, MELATONIN; SEROTONIN ANTAGONISTS; TRYPTAMINES;

EID: 44249109659     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.04.016     Document Type: Article

References (32)

1. Acarin L., Gonzalez B., Castro A.J., and Castellano B. Primary cortical glial reaction versus secondary thalamic glial response in the excitotoxically injured young brain: microglial/macrophage response and major histocompatibility complex class I and II expression. Neuroscience 89 (1999) 549-565
2. Agid Y., Buzsáki G., Diamond D.M., Frackowiak R., Giedd J., Girault J.A., Grace A., Lambert J.J., Manji H., Mayberg H., Popoli M., Prochiantz A., Richter-Levin G., Somogyi P., Spedding M., Svenningsson P., and Weinberger D. How can drug discovery for psychiatric disorders be improved?. Nat. Rev. Drug. Discov. 6 (2007) 189-201
3. Barks J.D., and Silverstein F.S. Excitatory amino acids contribute to the pathogenesis of perinatal hypoxic-ischemic brain injury. Brain Pathol. 2 (1992) 235-243
4. Bertaina-Anglade V., Mocaer E., and Drieu la Rochelle C. Anti-depressant-like action of S 20098 (agomelatine) in the learned helplessness test. Int. J. Neuropsychopharmacol. 5 (2002) S65
5. Bromidge S.M., Dabbs S., Davies D.T., Duckworth D.M., Forbes I.T., Ham P., Jones G.E., King F.D., Saunders D.V., Starr S., Thewlis K.M., Wyman P.A., Blaney F.E., Naylor C.B., Bailey F., Blackburn T.P., Holland V., Kennett G.A., Riley G.J., and Wood M.D. Novel and selective 5-HT2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines. J. Med. Chem. 41 (1998) 1598-1612
6. Conway S., Canning S.J., Howell H.E., Mowat E.S., Barrett P., Drew J.E., Delagrange P., Lesieur D., and Morgan P.J. Characterisation of human melatonin mt(1) and MT(2) receptors by CRE-luciferase reporter assay. Eur. J. Pharmacol. 390 (2000) 15-24
7. Dammann O., and Leviton A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatr. Res. 42 (1997) 1-8
8. Dicou E., Rangon C.M., Guimiot F., Spedding M., and Gressens P. Positive allosteric modulators of AMPA receptors are neuroprotective against lesions induced by an NMDA agonist in neonatal mouse brain. Brain Res. 970 (2003) 221-225
9. Dommergues M.A., Patkai J., Renauld J.C., Evrard P., and Gressens P. Proinflammatory cytokines and interleukin-9 exacerbate excitotoxic lesions of the newborn murine neopallium. Ann. Neurol. 47 (2000) 54-63
10. Dommergues M.A., Plaisant F., Verney C., and Gressens P. Early microglial activation following neonatal excitotoxic brain damage in mice: a potential target for neuroprotection. Neuroscience 121 (2003) 619-628
11. Follett P.L., Rosenberg P.A., Volpe J.J., and Jensen F.E. NBQX attenuates excitotoxic injury in developing white matter. J. Neurosci. 20 (2000) 9235-9241
12. Gressens P., and Spedding M. Strategies for neuroprotection in the newborn. Drug Discov. Today Ther. Strat. 1 (2004) 77-82
13. Gressens P., Marret S., Hill J.M., Brenneman D.E., Gozes I., Fridkin M., and Evrard P. Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. J. Clin. Invest. 100 (1997) 390-397
14. Grether J.K., Nelson K.B., Emery III E.S., and Cummins S.K. Prenatal and perinatal factors and cerebral palsy in very low birth weight infants. J. Pediatr. 128 (1996) 407-414
15. Hagberg B., Hagberg G., Olow I., and van Wendt L. The changing panorama of cerebral palsy in Sweden. VII. Prevalence and origin in the birth year period 1987-90. Acta Paediatr. 85 (1996) 954-960
16. Haynes R.L., Folkerth R.D., Keefe R.J., Sung I., Swzeda L.I., Rosenberg P.A., Volpe J.J., and Kinney H.C. Nitrosative and oxidative injury to premyelinating oligodendrocytes in periventricular leukomalacia. J. Neuropathol. Exp. Neurol. 62 (2003) 441-450
17. Husson I., Mesples B., Bac P., Vamecq J., Evrard P., and Gressens P. Melatoninergic neuroprotection of the murine periventricular white matter against neonatal excitotoxic challenge. Ann. Neurol. 51 (2002) 82-92
18. Husson I., Rangon C.M., Lelievre V., Bemelmans A.P., Sachs P., Mallet J., Kosofsky B.E., and Gressens P. BDNF-induced white matter neuroprotection and stage-dependent neuronal survival following a neonatal excitotoxic challenge. Cereb. Cortex 15 (2005) 250-261
19. Laudenbach V., Calo G., Guerrini R., Lamboley G., Benoist J.F., Evrard P., and Gressens P. Nociceptin/orphanin FQ exacerbates excitotoxic white-matter lesions in the murine neonatal brain. J. Clin. Invest. 107 (2001) 457-466
20. Loeliger M., Watson C.S., Reynolds J.D., Penning D.H., Harding R., Bocking A.D., and Rees S.M. Extracellular glutamate levels and neuropathology in cerebral white matter following repeated umbilical cord occlusion in the near term fetal sheep. Neuroscience 116 (2003) 705-714
21. Loo H., Hale A., and D'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int. Clin. Psychopharmacol. 17 (2002) 239-247
22. Loo H., Dalery J., Macher J.P., and Payen A. Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin- agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders. Encephale 29 (2003) 165-171
23. Manji H.K., Drevets W.C., and Charney D.S. The cellular neurobiology of depression. Nat. Med. 7 (2001) 541-547
24. Marret S., Mukendi R., Gadisseux J.F., Gressens P., and Evrard P. Effect of ibotenate on brain development: an excitotoxic mouse model of microgyria and posthypoxic-like lesions. J. Neuropathol. Exp. Neurol. 54 (1995) 358-370
25. McDonald J.W., Shapiro S.M., Silverstein F.S., and Johnston M.V. Role of glutamate receptor-mediated excitotoxicity in bilirubin-induced brain injury in the Gunn rat model. Exp. Neurol. 150 (1998) 21-29
26. Millan M.J., Gobert A., Lejeune F., Dekeyne A., Newman-Tancredi A., Pasteau V., Rivet J.M., and Cussac D. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J. Pharmacol. Exp. Ther. 306 (2003) 954-964
27. 2C antagonist properties, in major depressive disorder. Int. J. Neuropsychopharmacol. 10 (2007) 661-673
28. Papp M., Gruca P., Boyer P.A., and Mocaer E. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 28 (2003) 694-703
29. Plaisant F., Clippe A., Vander Stricht D., Knoops B., and Gressens P. Recombinant peroxiredoxin 5 protects against excitotoxic brain lesions in newborn mice. Free Radic. Biol. Med. 34 (2003) 862-872
30. Tahraoui S.L., Marret S., Bodenant C., Leroux P., Dommergues M.A., Evrard P., and Gressens P. Central role of microglia in neonatal excitotoxic lesions of the murine periventricular white matter. Brain Pathol. 11 (2001) 56-71
31. Volpe J.J. Neurobiology of periventricular leukomalacia in the premature infant. Pediatr. Res. 50 (2001) 553-562
32. Yang Q., Scalbert E., Delagrange P., Vanhoutte P.M., and O'Rourke S.T. Melatonin potentiates contractile responses to serotonin in isolated porcine coronary arteries. Am. J. Physiol. Heart Circ. Physiol. 280 (2001) H76-H82